Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS)

Journal of Physiology and Pharmacology

Volumn 60, Issue 2, 2009, Pages 71-76

  Miranda, Hugo F ^a   Pinardi, G ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Antinociception; COXs inhibitors; Isobolographic analysis; Morphine; Naltrindole; Writhing test

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DIPYRONE; KETOPROFEN; MELOXICAM; MORPHINE; NALTRINDOLE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE RECEPTOR; PARECOXIB; PIROXICAM; PROSTAGLANDIN;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; MALE; MOUSE; NOCICEPTION; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; WRITHING TEST;

ANALGESICS, OPIOID; ANIMALS; CYCLOOXYGENASE INHIBITORS; DRUG SYNERGISM; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED STRAINS; MORPHINE; NALTREXONE; PAIN; RECEPTORS, OPIOID, DELTA; SPINAL CORD;

EID: 68049104107     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Simmonds DL, Botting RM, Hla T. Cyclooxygenases isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437. (Pubitemid 39096597)
2. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
3. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006; 57 (Suppl 5): 113-124.
4. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73; 953-990.
5. Dionne RA, Lepinski AM, Gordon SM, Jaber L, Brahim JS, Hargreaves KM. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation. Clin Pharmacol Ther 2001; 70: 66-73. (Pubitemid 32678804)
6. Maves TJ, Pechman PS, Meller ST, Gebhart GF. Ketorolac potentiates morphine antinociception during visceral nociception in the rat. Anesthesiology 1994; 80: 1094-1101.
7. Taylor J, Mellstrom B, Fernaud I, Naranjo JR. Metamizol potentiates morphine effects on visceral pain and evoked cfos immunoreactivity in spinal cord. Eur J Pharmacol 1998; 351: 39-47. (Pubitemid 28300301)
8. Aguirre-Banuelos P, Granados-Soto V. Evidence for a peripheral mechanism of action for the potentiation of the antinociceptive effect of morphine by dipyrone J Pharmacol Toxicol Method 1999; 42: 79-85. (Pubitemid 30618979)
9. Fletcher D, Benoist JM, Gautron M, Guilbaud G. Isobolographic analysis of interactions between intravenous morphine, proparacetamol, and diclofenac in carrageenininjected rats. Anesthesiology 1997; 87: 317-326. (Pubitemid 27435374)
10. Lashbrook JM, Ossipov MH, Hunter JC, Raffa RB, Tallarida RJ, Porreca F. Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX 1-and COX 2-inhibitors in nerve-injured rats. Pain 1999; 82: 65-72. (Pubitemid 29287087)
11. Miranda HF, Silva E, Pinardi G. Synergy between the antinociceptive effects of morphine and NSAIDs. Can J Physiol Pharmacol 2004; 82: 331-338. (Pubitemid 39093699)
12. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597-652.
13. 1 receptor modulation of opioid analgesia in the mouse. J Pharmacol Exp Ther 2002; 300: 1070-1074.
14. Lucido AL, Morinville A, Gendron L, Stroh T, Beaudet A. Prolonged morphine treatment selectively increases membrane recruitment of δ-opioid receptors in mouse basal ganglia. J Mol Neurosci 2005; 25: 207-214. (Pubitemid 41389345)
15. Gendron L, Lucido AL, Mennicken F et al. Morphine and pain-related stimuli enhance cell surface availability of somatic δ-opioid receptors in rat dorsal root ganglia. J Neurosci 2006; 26: 953-962. (Pubitemid 43239576)
16. Miranda HF, Prieto JC, Pinardi G. Spinal synergy between nonselective cyclooxygenase inhibitors and morphine antinociception in mice. Brain Res 2005; 1049: 165-170. (Pubitemid 41072932)
17. Miranda HF, Sierralta F, Pinardi G. Neostigmine interactions with non steroidal anti-inflammatory drugs. Br J Pharmacol 2002; 135: 1591-1597. (Pubitemid 36132692)
18. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865-872. (Pubitemid 32761897)
19. Mehanna AS. NSAIDs: Chemistry and pharmacological actions. Am J Pharmac Edu 2003; 67: 1-7.
20. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation on nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33: 1027-1035. (Pubitemid 41002785)
21. Dembo G, Park SB, Kharasch ED. Central nervous system concentration of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102: 409-415.
22. Talley JJ, Bertenshaw SR, Brown DL et al. N-(((5-methyl-3-phenylisoxazol- 4-yl)-phenyl)sulfonyl)propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000; 43: 1661-1663. (Pubitemid 30304998)
23. Pinardi G, Prieto JC, Miranda HF. Analgesic synergism between intrathecal morphine and cyclooxygenase-2 inhibitors in mice. Pharmacol Biochem Behav 2005; 82: 120-124. (Pubitemid 41423494)
24. Rosenbrock H, Hagemeyer CE, Ditter M, Knoth R, Volk B. Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain. Neuroscience 2003; 117: 521-529. (Pubitemid 36263148)
25. Wong-Riley MT, Kageyama GH. Localization of cytochrome oxydase in the mammalian spinal cord and dorsal root ganglia, with quantitative analysis of ventral horn cells in monkeys. J Comp Neurol 1986; 245: 41-61.
26. Jean YH, Wen ZH, Chang YC et al. Intra-articular injection of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cingulate ligamenttransected knee in rats: role of excitatory amino acids. Osteoarthr Cartilage 2007; 15: 638-645.
27. Goodchild CS, Nadeson R, Cohen E. Supraspinal and spinal cord opioid receptors are responsible for antinociception following intrathecal morphine injections. Eur J Anaesthesiol 2003; 21: 179-185. (Pubitemid 38297913)
28. Sakurada S, Hayashi T, Yuhki M. Differential antinociceptive effects induced by intrathecallyadministered endomorphin-1 and endomorphin-2 in mice. Jpn J Pharmacol 2002; 89: 221-223. (Pubitemid 34884199)
29. Wu H, Sun HS, Darpolar M, Dunn III M, Tseng LF. Antinociceptive properties of oxymorphazole in the mouse. Eur J Pharmacol 2003; 473: 143-148.
30. Lorenzetti BB, Ferreira SH. Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. Inflamm Res 1996; 45: 308-311.
31. Aguirre-Banuelos P, Granados-Soto V. Evidence for the participation of the nitric-oxide-cyclic GMP pathway in the antinociceptive action of meloxicam in the formalin test. Eur J Pharmacol 2000; 395: 9-13. (Pubitemid 30227335)
32. Bujalska M. Effect of cyclooxygenase and NO synthase inhibitors administered centrally on antinociceptive action of acetaminophen (Part II). Pol J Pharmacol 2003; 55: 1001-1011. (Pubitemid 38128936)
33. + channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 2003; 26: 187-195.
34. Wasik A, Romanska I, Antkiewicz-Michaluk L. The effect of an endogneous compound 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol 2007; 58: 235-252. (Pubitemid 47026559)
35. Rodriguez Parkitna J, Korostynski M, Kaminska-Chowaniec D et al. Comparison of gene expression profiles in neurophatic and inflammatory pain. J Physiol Pharmacol 2006; 57: 401-414. (Pubitemid 44543875)